Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi/Regeneron's Great ODYSSEY ESCAPE – How Big Is Praluent's Apheresis Benefit?

Executive Summary

The full data for Sanofi/Regeneron's ODYSSEY ESCAPE study of their PCSK9 inhibitor Praluent confirm its use in reducing the need for expensive apheresis procedures in severe hypercholesterolemia patients, but the extent of the cost savings is still unclear.

You may also be interested in...



PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case

Sanofi and Regeneron’s Praluent could draw even with Amgen’s US Repatha in approved FDA indications in 2019. While the injectable PCSK9 inhibitors battle for payers and prescribers, Esperion is readying its oral bempedoic acid to join the lipid-lowering fray – and strategizing towards what could be the first statin intolerance indication.

Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data

Shire, Sanofi and Amgen were among the companies presenting at the Bank of America Merrill Lynch Global Healthcare Conference Sept. 14-16 in London. Here are some key takeaways from those presentations.

Praluent's ODYSSEY Continues As It Reduces Apheresis Need

Adding Sanofi/ Regeneron's Praluent to existing treatment regimens can reduce or even eliminate the need for expensive and cumbersome apheresis in patients with heterozygous familial hypercholesterolemia (HeFH), top-line data from the first Phase III study in this setting show.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel